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Background
External Ventricular Drainage (EVD) infections are a
serious complication, and the period of risk extends
until the device is removed. The causative bacteria of
EVD and shunt infections are similar but there are
more multi – resistant strains such as MRSA and gram
negative bacteria in EVD infections, particularly when
the patient is in intensive care. To counter this, we have
development an antimicrobial EVD catheter with a
broad spectrum to protect against these multi-resistant
bacteria. Thus, the aim of this study was to evaluate
the antimicrobial activity of this catheter against multi-
resistant Staphylococcus epidermidis, MRSA, and gram
negatives using clinically predictive in vitro tests.
Materials and methods
Medical grade silicone catheter tubing (Codman) was
impregnated with antimicrobials: 1% triclosan, 1% tri-
methoprim and 0.2% rifampicin respectively. Three meth-
ods were used to evaluate the antimicrobial activity of the
catheter. The Serial Plate Transfer Test (SPTT) is a screen-
ing test for duration of antimicrobial activity and to moni-
tor resistance. Impregnated catheter segments were placed
onto agar plates seeded with bacteria and incubated. Seg-
ments were removed daily and placed on fresh plates and
reincubated. The inhibition zone was measured across the
short axis. This was repeated until no inhibition zones
were seen. The time taken to kill 100% of bacteria attached
to catheter segments (tK100), was determined by first coat-
ing the catheter segments with a protein conditioning film,
then allowing the bacteria to adhere to plain and antimi-
crobial catheter segments and incubating them. Samples
were retrieved daily, sonicated to remove the adherent
bacteria, and the sonicate cultured quantitatively to detect
bacterial growth. Thirdly, a simulated in vitro model was
used to determine the ability of the antimicrobial catheter
to resist successive bacterial challenges every 14 days under
constant perfusion, designed to mimic the CSF flow.
Results
The SPTT showed duration of antimicrobial activity for
more than 80 days. The tK100 showed that it takes
between 24-48 hours to kill all the bacteria attached to
the catheter. The in vitro model showed that the catheter
protected against bacterial colonization after 7 successive
challenges (ie more than 80 days), without developing
resistance.
Conclusions
The catheter demonstrated a broad spectrum of antimi-
crobial activity and a prolonged duration of activity against
multi- resistant bacteria. The clinically predictive tests
indicate that the catheter is likely to reduce significantly
EVD infections caused by multi-resistant superbugs found
among patients on intensive care and high-dependency
units.
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